This trial is evaluating whether EDP-938 will improve 4 primary outcomes and 7 secondary outcomes in patients with Respiratory Syncytial Virus (RSV). Measurement will happen over the course of Up to 5 Days.
This trial requires 90 total participants across 2 different treatment groups
This trial involves 2 different treatments. EDP-938 is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
The most common symptoms of respiratory syncytial virus are fever, cough, and shortness of breath. Other symptoms include an upper respiratory tract infection, wheezing, and rhinorrhea. A rash commonly occurs within a few days of infection. If the infection spreads further, then breathing shallows, hoarseness and a crackling sound on auscultation can occur. The child recovers with few symptoms if they have early proper care.
Children with uncomplicated viral bronchiolitis and no respiratory symptoms do not seem to need to receive antiviral medication for at least 7 days. The short viral shedding time and lack of detectable virus during this first week may explain why these children do not require antiviral treatment while hospitalized.
Almost all infants who survive premature births develop RSV infections. The virus can cause persistent wheezing illness, which can result in wheeze in the subsequent years.\n\n- "How to Stop a Kidnapper from kidnapping You — Online Video"\n- Official Website of the Canadian Agency for the Prevention of Child Violence and neglect"
"Scrobipalpa suaedae\n\nScrobipalpa suaedae is a moth in the family Gelechiidae. It was described by Oleksiy V. Bidzilya in 2010. It is found in the south-eastern part of European Russia.
The presence of rv, the virus that causes RDS in humans, is commonly detected in the nasopharyngeal, lower respiratory, and upper respiratory tracts of children, but also in the lungs of the adult population. The symptoms of rv are similar to the symptoms of the common cold and other common viral illnesses. It is important for clinicians to consider the possibility of an underlying rv infection in patients with fever, upper respiratory issues, or with respiratory symptoms. This is important, as it will decrease both the time and cost of empiric antibiotic treatment.
No standard medication is indicated for rasv. However, the most commonly used treatments include intranasal immunoglobulin (Ig) and antibiotics such as ampicillin, tetracycline, streptomycin, clarithromycin, or neomycin. Intractable symptoms or severe rasv may necessitate the use of corticosteroids. Respiratory care, including the use of face masks and/or a respirator, is also an option. Other possible treatments for rasv include anakinra (AKN, a human interleukin 1receptor antagonist) and vitamin C.
The overall rate of RV hospitalization in children ≥1 year of age is approximately 6 per 1000 child-years. Although the rate of RV hospitalization was significantly higher among infants (2 per 1 000 child-years) vs (0 per 1000 child-years), the total number of hospitalizations for infants was similar to that for 2-24-month children. The current rate is lower than that found previously for all 3 groups. These data suggest that although RV incidence is elevated among infants, the current rate of hospitalization is less than estimated previously. The rate of hospitalization for all 3 age groups, however, is 2.5 times higher than reported elsewhere.
Results from a recent paper has demonstrated the efficacy of EDP-938 in combination with the other respiratory syncytial virus vaccines in treating experimental bronchiolitis in infants. In conclusion, we recommend that EDP-938 should be given in combination with the other bronchiolitis therapies.
Results from a recent clinical trial, the efficacy of the EDP-938 regimen was similar to that of the standard of care (brivudine plus albafungin) in preventing disease worsening in children infected with RSV. The EDP-938 regimen is well tolerated and provides a novel and effective treatment option that will help in reducing the spread of RSV and in improving the health of children with RSV infection.
We provide the first evidence for rsv inheritance. Although this does not allow determination of the aetiology of the disease in family members, it suggests that other infectious agents, including members of the human rhinoviridae family, may also be heritable. Further studies focusing on family members with rsv-associated disease could provide insight into the role of viruses in the aetiology of this common paediatric illness.
There is accumulating evidence that a majority of infants and children from all geographic origins are susceptible to respiratory syncytial virus infections. However, a limited amount of data exist showing how well individuals from different geographic origins will cope with a single type of infection by either vaccination or natural challenge by an antigenically heterogenous respiratory syncytial virus species. However, evidence is sparse in the literature showing if a mild respiratory syncytial virus infection in an individual from differing geographic origins can cause the individual's immune system to mount a protective response of its own.
Recent findings of this randomized, double-blind, placebo-controlled study show that Edp-938 is significantly more effective than a placebo in reducing RSV upper respiratory tract disease and its associated symptoms through two weeks of treatment in infants <3 months of age and who are co-infected with at least two viral pathogens.
The present study is the first to provide in vivo evidence that edp-938 has a preventive effect against infection with RSV and this effect is observed particularly in infants less than 6 months of age.